It is widely considered that serum uric acid (SUA), the final breakdown product of purine metabolism in humans, may represent a major cardiovascular risk factor and contribute to adverse health outcomes and mortality [1–6]. Elevated concentrations of SUA have been implicated in the development of hypertension, metabolic syndrome, type 2 diabetes, coronary artery disease, left ventricular hypertrophy, atrial fibrillation, myocardial infarction, stroke, heart failure and chronic kidney disease [7].
